Shopping Cart
Remove All
Your shopping cart is currently empty
ESI-09 is a new-typel noncyclic nucleotide EPAC antagonist.The IC50 values of ESI-09 for EPAC1 and EPAC2 is 3.2 and 1.4 μM, respectively.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $35 | In Stock | In Stock | |
| 5 mg | $56 | In Stock | In Stock | |
| 10 mg | $89 | In Stock | In Stock | |
| 25 mg | $177 | In Stock | In Stock | |
| 50 mg | $320 | In Stock | In Stock | |
| 100 mg | $482 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $61 | In Stock | In Stock |
| Description | ESI-09 is a new-typel noncyclic nucleotide EPAC antagonist.The IC50 values of ESI-09 for EPAC1 and EPAC2 is 3.2 and 1.4 μM, respectively. |
| Targets&IC50 | EPAC1:3.2 μM, EPAC2:1.4 μM |
| In vitro | In WT C57BL/6 mice, ESI-09 (10 mg/kg/d, i.p.) prevents SFG Rickettsiosis by inhibiting EPAC1. |
| In vivo | ESI-09 specifically inhibits intracellular EPAC-mediated activation of Rap1 and phosphorylation of Akt, as well as EPAC-mediated secretion in pancreatic β-cells. In pancreatic cancer cells induced by 007-AM, ESI-09 reduces cell adhesion and inhibits cell migration. In Schwann cells stimulated by CPT-cAMP, ESI-09 significantly suppresses cell differentiation and myelination. Additionally, in SC neuronal cultures, ESI-09 notably decreases the number of O1-positive and MBP-positive cells. |
| Molecular Weight | 330.77 |
| Formula | C16H15ClN4O2 |
| Cas No. | 263707-16-0 |
| Smiles | CC(C)(C)c1cc(no1)C(=O)C(=NNc1cccc(Cl)c1)C#N |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 33.1 mg/mL (100.07 mM), Sonication is recommended. Ethanol: 6.6 mg/mL (19.95 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.05 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.